BioCardia rejigs phase 3 heart failure data to find a path forward for cell therapy

BioCardia’s data safety monitoring board already warned that the phase 3 CardiAMP cell therapy heart failure trial was not going to make the primary endpoint. And so the California biotech is showcasing some other endpoints instead, hoping to persuade investors that the autologous cell therapy has a future.